OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC

ESMO Open

article

M.S. Hussain¹  J. Klugarova¹  M. Klugar¹ 

[1] Faculty of Medicine, Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, Masaryk University

关键词: Durvalumab;    Lung Cancer;    NSCLC;   

DOI  :  10.1016/j.esmoop.2022.100716

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background: Non-small cell lung cancer (NSCLC) is the most common form of lungcancer. Recently, Durvalumab was approved as a potential immunotherapy for themanagement of unresectable stage III NSCLC. To date, economic studies fromdifferent parts of the world presented varying findings. So, the objective of this studywas to assess the cost-effectiveness of durvalumab consolidation therapy versus noconsolidation therapy in patients with unresectable stage III NSCLC.Methods: PubMed, Embase, and Cochrane Central databases were searched tillMarch 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC who had not progressed afterdefinitive chemoradiotherapy. Eligible studies were screened by two reviewersindependently and the quality of included studies was evaluated using the updatedversion of Consolidated Health Economic Evaluation Reporting Standards (CHEERS20222) checklists. By taking into account purchasing power parity, incremental costeffectiveness ratio (ICER) data were converted to 2022 US dollars ($).Results: A total of seven studies were found to be eligible for inclusion. The majorityof studies were conducted in the US (n ¼ 3), while one study each was conducted inChina, Italy, Switzerland, and the UK. The healthcare payers’ perspective was the mostcommon study perspective among the included studies and the time horizon variedfrom 5 years to a lifetime. Half of the included studies received funding from Industry.Four included studies used the Markov model, while two studies employed the semiMarkov model and, the remaining one study used the decision-analytic model. TheICER of durvalumab consolidation therapy after unresectable stage III NSCLC in the USwas found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years(QALY). Likewise, the ICER of durvalumab in European countries was found to be inthe range of $62,021 to $76,068 per QALY. Durvalumab was found to be cost-effectiveamong all the included studies as the ICER was below the implemented countryspecific willingness-to-pay thresholds.Conclusions: Durvalumab consolidation therapy was found to be cost-effectivecompared to no consolidation therapy after chemoradiotherapy in stage-III NSCLCpatients.

【 授权许可】

CC BY|CC BY-NC-ND